Bifosfonaatti-intioleranssi ja OP

Bone-forming agents in non-responders to bisphosphonates

Juliet CompstonEmail the author Juliet Compston

Published: 26 July 2017

DOI: http://dx.doi.org/10.1016/S0140-6736(17)31824-X

Osteoporosis is a chronic disease requiring long-term treatment. Oral bisphosphonates, which act by inhibiting bone resorption, are most commonly prescribed but inadequate response, development of intolerance, or fear of long-term side-effects sometimes necessitate change to an alternative therapy.¹ One option is to switch to teriparatide, a bone-forming agent, but enthusiasm for this strategy is tempered by the blunting of the bone mineral density (BMD) response to teriparatide seen in patients previously treated with antiresorptives.

4.1. 2018 Lancet sitaatti